Dark

LGND
Ligand Pharmaceuticals Inc.
stock NASDAQ

At Close

May 16, 2025 3:59:30 PM EDT

104.54USD+1.034%(+1.07)79,629

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-103.47)0

After-hours

May 16, 2025 4:00:30 PM EDT

104.54USD0.000%(0.00)1,042

OverviewOptionsHistoricalExchangesShortsNews

Dec 22, 2021

08:03AM EST Ligand's Partner CStone Pharmaceuticals Receives Approval In China For Sugemalimab For First-Line Treatment Of Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy Benzinga

Dec 21, 2021

04:02PM EST Ligand And GSK Expand Global Collaboration And License Agreement; Ligand To Receive An Upfront Payment Of $10M And Is Eligible For Development And Regulatory Milestones Up To $67.5M Benzinga

Dec 13, 2021

10:00AM EST Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 GlobeNewswire Inc

Nov 9, 2021

05:18PM EST Ligand Pharmaceuticals Reaffirms FY21 Guidance Benzinga

05:18PM EST Ligand Pharmaceuticals Q3 EPS $1.58 Beats $1.04 Estimate, Sales $64.83M Beat $55.65M Estimate Benzinga

05:12PM EST Shares of Ligand Pharmaceuticals Inc. (LGND) gained 5% in extended trading hours on Tuesday after the company's third-quarter profit and revenues trumped Wall Street estimates. The company also reaffirmed its full year outlook. RTTNews

05:04PM EST Recap: Ligand Pharmaceuticals Q3 Earnings Benzinga

04:32PM EST Ligand Pharma Q3 EPS $0.80 Vs. Loss $0.42 Year Ago RTTNews

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Oct 21, 2021

01:13PM EDT Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals Benzinga

12:12PM EDT Ligand And CR Double-Crane Enter Collaboration Agreement To Develop An Oral COVID-19 Therapeutic Using Ligand's BEPro Technology Benzinga

Sep 22, 2021

06:58AM EDT Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $180 Benzinga

Aug 31, 2021

02:01PM EDT Why Digital Turbine's Stock Is Trading Higher Today Benzinga

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 30, 2021

07:00PM EDT Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse PR Newswire

05:18PM EDT S&P Dow Jones Indices Announces 'Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600' Benzinga

04:02PM EDT Ligand Pharma Partner Gloria Biosciences Receives Approval In China For Zimberelimab For Treatment Of Recurrent, Refractory Classical Hodgkin's Lymphoma Benzinga

Aug 16, 2021

02:55PM EDT Ligand Pharma Highlights Partner Travere Therapeutics Topline Interim Results From Ongoing Phase 3 PROTECT Study Of Sparsentan; Co. Notes Is Entitled To Receive $5.9M Milestone Upon New Drug Application Submission Benzinga

10:02AM EDT Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy Of Oral Lasofoxifene Versus Intramuscular Fulvestrant; NOTE: Co. Licensed Lasofoxifene From Ligand Benzinga

10:00AM EDT Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 GlobeNewswire Inc

Aug 12, 2021

11:02AM EDT What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months Benzinga

Jul 30, 2021

09:47AM EDT Roth Capital Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $190 Benzinga

Jul 29, 2021

05:19PM EDT Ligand Pharmaceuticals Inc (LGND) revealed earnings for its second quarter that increased from last year. RTTNews

04:51PM EDT Ligand Pharma Q2 EPS $1.79 Vs. $1.32 Year Ago RTTNews

04:45PM EDT Ligand Sees FY21 Adj. EPS $5.80-$6.05 vs $6.12 Est., Sales $265M-$275M vs $280.44M Est. Benzinga

04:42PM EDT Ligand Pharmaceuticals Q2 Adj. EPS $1.63 Beats $1.34 Estimate, Sales $84.70M Beat $70.41M Estimate Benzinga

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 28, 2021

04:00PM EDT Ligand Pharmaceuticals to further empower the OmniAb(r) and xPloration(tm) antibody discovery platforms PR Newswire

10:40AM EDT Ligand Pharmaceuticals Earnings Preview Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 21, 2021

09:16AM EDT Ligand Partner Jazz Pharmaceuticals Launches RYLAZE; Ligand Expects To Receive $7M In Milestone Payments Benzinga

Jul 19, 2021

08:07AM EDT Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE For The Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes; Under The Terms Of The Licensing Agreement With Merck, Ligand Earned A $2M Milestone Payment Benzinga

Jun 28, 2021

10:13AM EDT Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical GlobeNewswire Inc

Jun 2, 2021

09:01AM EDT GenScript Biotech And Ligand Pharmaceuticals Enter Global OmniAb Licensing Agreement; Financial Terms Not Disclosed Benzinga

May 4, 2021

10:18AM EDT Barclays Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $190 Benzinga

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

May 3, 2021

11:14PM EDT Ligand Pharmaceuticals Inc. (LGND) reported that its net income for the first quarter of 2021 was $18.1 million or $1.05 per share, compared to net loss of $24.1 million, or $1.46 per share, for the same period in 2020. RTTNews

05:17PM EDT Ligand Pharma Q1 EPS $1.05 Vs Loss $1.46 Last Year RTTNews

04:58PM EDT Recap: Ligand Pharmaceuticals Q1 Earnings Benzinga

04:06PM EDT Ligand Pharmaceuticals Q1 EPS $1.41 Beats $1.12 Estimate, Sales $55.15M Miss $62.85M Estimate Benzinga

04:13AM EDT Earnings Scheduled For May 3, 2021 Benzinga

Feb 25, 2021

09:55AM EST Here Are The Stocks With The Highest Short Interest Rate Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 4, 2021

01:17PM EST Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $198 Benzinga

08:50AM EST Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $200 Benzinga

06:14AM EST HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $310 Benzinga

Feb 3, 2021

03:11PM EST Ligand Pharmaceuticals shares were trading higher after the company reported better-than-expected Q4 EPS and sales results. Benzinga

07:58AM EST Ligand Pharmaceuticals: Q4 Earnings Insights Benzinga

07:48AM EST While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company Ligand Pharmaceuticals Inc. (LGND) raised its adjusted earnings and revenue guidance for the full-year 2021. RTTNews

07:35AM EST Ligand Pharma Q4 Net Income $5.8 Mln Or $0.35/Shr Vs Loss Of $7.4 Mln Or $0.43/Shr Last Year RTTNews

07:33AM EST Ligand Raises FY21 Adj. EPS Guidance From $6.00 To $6.15 vs $6.09 Est., Raises Sales Guidance From $285M To $291M vs $289M Est. Benzinga

07:31AM EST Ligand Raises FY21 Guidance Benzinga

07:31AM EST Ligand Pharmaceuticals Q4 EPS $1.62 Beats $0.99 Estimate, Sales $69.99M Beat $54.09M Estimate Benzinga

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

07:30AM EST Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

04:00AM EST Earnings Scheduled For February 3, 2021 Benzinga

Feb 2, 2021

11:59AM EST Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis Business Wire

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 27, 2021

10:07AM EST Stocks That Hit 52-Week Highs On Wednesday Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

08:30AM EST Ligand's Fourth Quarter Financial Results to be Reported February 3rd Business Wire

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 13, 2021

08:34AM EST Ligand To Receive $1.5 Mln Milestone Payment From Merck Triggered By FDA's Acceptance Of BLA For V114 RTTNews

08:34AM EST Ligand Receives $1.5M Milestone Payment From Merck, Triggered By FDA Acceptance For Review Of BLA For V114 Benzinga

08:30AM EST Ligand Receives Milestone Payment from Merck Business Wire

Dec 21, 2020

08:42AM EST Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen's Discovery Technology to Target Neurological Disorders Benzinga

08:39AM EST Ligand Announces Collaboration And License Agreement With GSK RTTNews

08:30AM EST Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen's Discovery Technology to Target Neurological Disorders Business Wire

Nov 23, 2020

08:38AM EST Ligand Pharmaceuticals Says Two Large Multinational Pharmaceutical Partners With License To Omniab Have Reached Clinical Development Milestones With Programs; Says Progress By Partners Resulted In Total Of $4.5M In Milestone Payments Being Earned By Co. Benzinga

08:30AM EST Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb(r) Antibodies Business Wire

Nov 6, 2020

02:16PM EST Ligand's Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT(tm) for the Treatment of Status Epilepticus in Adult and Pediatric Patients Business Wire

Oct 30, 2020

08:25AM EDT Recap: Ligand Pharmaceuticals Q3 Earnings Benzinga

08:21AM EDT While reporting financial results for the third quarter on Friday, biopharmaceutical company Ligand Pharmaceuticals Inc. (LGND) reiterated its adjusted earnings and revenue guidance for the full-year 2020. RTTNews

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

08:04AM EDT Ligand Sees FY21 Sales ~$285M vs $277M Estimate, Adj. EPS $6 vs $5.89 Est. Benzinga

08:04AM EDT Ligand Pharma Q3 Net Loss $6.7 Mln Or $0.42/Shr Vs Loss Of $15.3 Mln Or $0.81/Shr Last Year RTTNews

08:03AM EDT Ligand Sees FY20 Adj. EPS $3.95 vs $3.91 Estimate, Sales ~$170M vs $170.22M Est. Benzinga

08:03AM EDT Ligand Pharmaceuticals Q3 Adj. EPS $1.04 Beats $0.98 Estimate, Sales $41.80M Miss $44.36M Estimate Benzinga

08:00AM EDT Ligand Reports Third Quarter 2020 Financial Results Business Wire

04:07AM EDT Earnings Scheduled For October 30, 2020 Benzinga

Oct 23, 2020

08:35AM EDT Ligand Says Its Captisol Technology Plays Key Role In The Manufacture Of Gilead's Remdesivir RTTNews

08:33AM EDT Ligand Pharma Congratulates Gilead On FDA Approval Of Remdesivir; BZ NOTE: Remdesivir Is Formulated With Ligand's Capitsol Technology Benzinga

08:30AM EDT Ligand's Captisol Technology Plays Key Role in the Manufacture of Gilead's Veklury, the First FDA-Approved COVID-19 Treatment Business Wire

Oct 22, 2020

04:49PM EDT FDA Approves Gilead's Remdesivir For Treatment Of Hospitalized COVID-19 Patients Benzinga

Oct 21, 2020

12:17PM EDT Craig-Hallum Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $195 Benzinga

Oct 20, 2020

02:11PM EDT Ligand Sees FY21 Sales $285M vs $249M Estimate, Adj. EPS $6 vs $6.50 Est. Benzinga

02:08PM EDT UPDATE: Ligand Raises FY20 Sales Guidance From ~$140M To ~$170M vs $168.8M Estimate Benzinga

02:07PM EDT UPDATE: Ligand Raises FY20 Guidance: Adj. EPS From $3.62 To $3.95 vs $4.10 Estimate Benzinga

02:06PM EDT Ligand Raises Guidance Benzinga

02:05PM EDT Ligand Provides Highlights from Today's Investor Day Event Business Wire

Oct 19, 2020

04:02PM EDT Ligand's Third Quarter Financial Results to be Reported October 30th Business Wire

Oct 13, 2020

09:31AM EDT Sermonix Doses First Patient In Phase 2 Clinical Trial Collaboration Studying Ligand Pharmaceutical's Lasofoxifene In Combination With Eli Lilly, Co's Abemaciclib Benzinga

Oct 12, 2020

09:04AM EDT Ligand Pharma Sells Vernalis Research Operations And Internal Programs To HitGen For $25 Mln In Cash RTTNews

09:00AM EDT Ligand to Divest Vernalis Research Operations Business Wire

06:11AM EDT Hitgen Inc Announces It Has Signed An Agreement With Ligand Pharmaceuticals To Acquire Vernalis Limited For $25M Benzinga

Oct 2, 2020

08:00AM EDT Ligand to Host Virtual Investor Day on October 20th Business Wire

Oct 1, 2020

08:28AM EDT Ligand Pharmaceuticals Completes Acquisition Of Pfenex; PFNX To Cease Trading On NYSE RTTNews

08:24AM EDT Ligand Completes Acquisition of Pfenex Inc. Business Wire

Sep 30, 2020

08:07AM EDT Ligand Announces Expiration Of Tender Offer For Shares Of Pfenex RTTNews

Sep 29, 2020

09:06AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

08:47AM EDT Roth Capital Reiterates Buy on Ligand Pharmaceuticals, Raises Price Target to $195 Benzinga

Sep 23, 2020

08:15AM EDT Ligand Pharmaceuticals Says On Sept 21, Co's Unit, CyDex Pharmaceuticals, Entered Into An Amendment To Supply Agreement With Gilead Sciences, Agreed To Supply Up To 150% Of Forecasted Amount Of Captisol; Co. Notes Captisol Is A Remdesivir Component Benzinga

08:03AM EDT Ligand Pharmaceuticals Inc Sees 2021 Captisol Material Sales Of About $200M Benzinga

08:00AM EDT Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million Business Wire

Sep 10, 2020

08:06AM EDT Ligand Expands Its OmniAb Antibody Discovery Platform Through The Acquisition Of xCella Biosciences And Taurus Biosciences; xCella Will Get Acquired For $7M And Taurus For $5M Benzinga

Sep 1, 2020

04:02PM EDT Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference Business Wire

Aug 31, 2020

09:03AM EDT Ligand Begins Previously Announced Cash Tender Offer To Acquire Pfenex RTTNews

09:01AM EDT Ligand Commences Previously Announced Cash Tender Offer To Acquire Pfenex Inc. At $12/Share In Cash Plus One Non-transferable Contractual Contingent Value Right Per Share Representing The Right To Receive A Contingent Payment Of $2.00 In Cash Benzinga

09:00AM EDT Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. Business Wire

Aug 25, 2020

04:20PM EDT Ligand Highlights Immunovant Earlier Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis Benzinga

04:15PM EDT Ligand OmniAb(r) Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis Business Wire

Aug 24, 2020

08:38AM EDT Ligand : Amgen's KYPROLIS Approved By FDA As Combination Regimen with DARZALEX And Dexamethasone For R/R MM RTTNews

08:34AM EDT Ligand Announces Amgen's KYPROLIS Approved By FDA As Combination Regimen With DARZALEX And Dexamethasone In Once- And Twice-Weekly Dosing Regimens For Patients With Relapsed/Refractory Multiple Myeloma Benzinga

08:30AM EDT Ligand Announces Amgen's KYPROLIS(r) Approved by FDA as Combination Regimen with DARZALEX(r) and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma Business Wire

Aug 12, 2020

10:33AM EDT (PFNX) Alert: Johnson Fistel Investigates Proposed Sale of Pfenex; Are PR Newswire

Aug 11, 2020

01:11PM EDT P/E Ratio Insights for Ligand Pharmaceuticals Benzinga

01:05PM EDT PFENEX INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces GlobeNewswire Inc

06:50AM EDT A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street Benzinga

Aug 10, 2020

05:36PM EDT Ligand to Acquire Pfenex Inc. Business Wire

Aug 7, 2020

08:54AM EDT CStone Announces That OmniAb-Derived CS1001 Phase 3 Trial Met Primary Endpoint As First-Line Treatment In Stage IV Squamous, Non-Squamous Non-Small Cell Lung Cancer, Announces Plan To Submit New Drug Application Benzinga

08:34AM EDT Ligand: CStone Report OmniAb-derived Anti-PD-L1 MAb CS1001 Plus Chemotherapy Met Pre-specified Primary Endpoint RTTNews

08:30AM EDT CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application Business Wire

Aug 4, 2020

11:37AM EDT Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $145 Benzinga

Aug 3, 2020

10:21AM EDT Ligand Pharmaceuticals shares are trading higher after the company raised its FY20 EPS and sales guidance above analyst estimates. Benzinga

07:45AM EDT While reporting its financial results for the second quarter on Monday, Ligand Pharmaceuticals Inc. (LGND) said it now expects 2020 total revenues to be about $165 million and adjusted earnings per share to be $4.10, up from previous guidance for total revenues of approximately $140 million and adjusted earnings per share of $3.65. RTTNews

07:38AM EDT Ligand Pharmaceuticals Raises FY2020 Adj EPS Guidance from $3.65 to $4.10 vs $3.71 Est; Raises FY2020 Sales Guidance from $140.00M to $165.00M vs $142.45M Est Benzinga

07:34AM EDT Ligand Pharma Q2 Net Income $22.1 Mln Or $1.32/Shr Vs Loss Of $14.4 Mln Or $0.74/shr Last Year RTTNews

07:30AM EDT Ligand Reports Second Quarter 2020 Financial Results Business Wire

04:13AM EDT Earnings Scheduled For August 3, 2020 Benzinga

Jul 16, 2020

04:28PM EDT Ligand's Second Quarter Financial Results to be Reported August 3rd Business Wire